Zacks.com Announces That Nadine Wong Highlights the Following Stock: Acambis.Business Editors CHICAGO--(BUSINESS WIRE)--March 9, 2004 Nadine Wong can help build up your portfolio's immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. with a biotechnology stock that could vaccinate vac·ci·nate v. To inoculate with a vaccine in order to produce immunity to an infectious disease such as diphtheria or typhus. vac your investments from market ills. Read her commentary and stock profile to stay in prime shape. Read about Acambis (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ACAM ACAM American College for Advancement in Medicine ACAM Autorité de Contrôle des Assurances et des Mutuelles (French organization regulating insurance companies and mutual funds) ACAM Annonces Classees A Montreal ). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84 Here are the highlights from the Featured Expert column: An Ounce of Prevention In her latest issue, Nadine Wong discusses vaccines and the protection they provide from infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. . Vaccines are gaining more and more attention as new infectious agents are being discovered. One company that she highlights in the report is Acambis (NASDAQ:ACAM), a leading developer of vaccines to prevent and treat infectious diseases infectious diseases: see communicable diseases. . Moreover, the company is well known for their ability to produce smallpox vaccines (the company is the only one who is allowed to produce the smallpox vaccine). The company was given a U.S. contract to manufacture more smallpox vaccine for the government to stockpile in the event of a bioterrorist attack. Acambis is also developing other vaccines, including for West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis. , which is a serious problem here in the U.S., and for Dengue dengue or breakbone fever or dandy fever Infectious, disabling mosquito-borne fever. Other symptoms include extreme joint pain and stiffness, intense pain behind the eyes, a return of fever after brief pause, and a characteristic rash. and Japanese encephalitis Japanese Encephalitis Definition Japanese encephalitis is an infection of the brain caused by a virus. The virus is transmitted to humans by mosquitoes. virus, which are problems overseas. Overall, Acambis will generate revenue from the sale of the smallpox vaccine to the U.S. and eventually from the other vaccine candidates if and when they are marketed. Wong envisions Acambis to do well in the short term as investors gravitate grav·i·tate intr.v. grav·i·tat·ed, grav·i·tat·ing, grav·i·tates 1. To move in response to the force of gravity. 2. To move downward. 3. to the story: further smallpox government contracts and potential retail distribution of smallpox vaccine. Eventually, the story would slowdown as the need for smallpox vaccines reduces. As a result, revenues and profits will decline, but then other vaccines would take its place. Read more of Nadine Wong's information on Acambis by clicking: http://at.zacks.com/?id=85 About Zacks Featured Experts To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. Recommendations from Featured Experts Highlighted in FREE Investment Newsletter The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86 About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://at.zacks.com/?id=87 Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion